Alemtuzumab in the treatment of relapsed acute lymphoid leukaemia.
Piccaluga
P P
PP
Martinelli
G
G
Malagola
M
M
Rondoni
M
M
Bonifazi
F
F
Bandini
G
G
Visani
G
G
Baccarani
M
M
D000074323:Alemtuzumab; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000912:Antibodies, Neoplasm / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D004921:Erythropoietin / Q000008:administration & dosage; D016179:Granulocyte Colony-Stimulating Factor / Q000008:administration & dosage; D006801:Humans; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000188:drug therapy* / Q000473:pathology; D012008:Recurrence
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000912:Antibodies, Neoplasm; D000970:Antineoplastic Agents; D004921:Erythropoietin; D016179:Granulocyte Colony-Stimulating Factor; D000074323:Alemtuzumab